Annals of Allergy Asthma & Immunology最新文献

{"title":"From the Pages of AllergyWatch.","authors":"Stanley M Fineman, Samantha M Knox, Sarah Spriet, Iris Otani","doi":"10.1016/j.anai.2025.05.020","DOIUrl":"https://doi.org/10.1016/j.anai.2025.05.020","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infectious complications of atopic dermatitis, an update.","authors":"Vivian Wang, Petrus Johannes Jansen van Rensburg, Juri Boguniewicz, Peck Y Ong","doi":"10.1016/j.anai.2025.05.021","DOIUrl":"https://doi.org/10.1016/j.anai.2025.05.021","url":null,"abstract":"<p><strong>Objective: </strong>The current review aims to summarize recent advances in skin barrier lipid dysregulation, various aspects of innate and adaptive immunity that contribute to the pathogenesis of infectious complications of AD. The review also presents practical guidance in the management and prevention of infections in AD. The role of current AD therapy in infection is also discussed in detail.</p><p><strong>Data sources: </strong>Published literature obtained through PubMed searches.</p><p><strong>Study selection: </strong>Studies relevant to the mechanisms of infection in AD, clinical implications, treatments, prevention and future therapy.</p><p><strong>Results: </strong>A decrease in lipids with long-chain fatty acids and omega-esterified ceramides renders the skin barrier of AD more hydrophobic and susceptible to S. aureus. Self-DNA and RNase inhibitor interfere with the activity of host antimicrobial peptides/proteins against S. aureus. CD1a-restricted T cells against S. aureus lipid antigen may play a pathogenic role in AD. Meta-analyses showed that dupilumab, which targets IL-4 and IL-13, decreases the frequency of infections in AD, whereas oral Janus kinase inhibitors, which has a broader immunosuppressing effect, is associated with an increased risk of herpes zoster and herpes-related infections.</p><p><strong>Conclusion: </strong>Infectious complications remain a major co-morbidity in uncontrolled AD. Clinicians will continue to face these challenges in routine practice. Successful prevention and treatment will depend on our understanding of AD pathophysiology.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diversity, Equity, and Inclusion in Asthma Clinical Trials: A Cross-Sectional Analysis.","authors":"Rachel Hazlitt, Khanh Nguyen, Andrew Wilson, Payton Clark, Merhawit Ghebrehiwet, Josh Autaubo, Natalie Turner, Bradley Anderson, Alicia Ito Ford, Matt Vassar","doi":"10.1016/j.anai.2025.05.022","DOIUrl":"https://doi.org/10.1016/j.anai.2025.05.022","url":null,"abstract":"<p><strong>Background: </strong>Health inequity exists across the scientific and medical community, specifically in the development and design of clinical trials. There is a lack of diversity and representation of historically marginalized groups in the current landscape of clinical research, and our primary objective for this study was to evaluate recruitment and retention strategies for historically marginalized patients in asthma clinical trials.</p><p><strong>Objective: </strong>To evaluate the extent to which asthma clinical trials employ recruitment and retention strategies that promote diversity and to identify persistent gaps in the representation of historically marginalized populations.</p><p><strong>Methods: </strong>We performed a search of major databases - MEDLINE and Embase - to identify clinical trials that performed various interventions and treatment modalities for asthma. Screening and data extraction were performed in a masked and duplicate fashion to limit error. General study characteristics along with recruitment and retention strategies were recorded.</p><p><strong>Results: </strong>121 clinical trials were included in our study. Of the included studies, forty-two (42/121, 34.7%) reported the use of retention and recruitment strategies. Eighteen (18/121, 14.9%) studies explicitly stated their diversity goals for the participants.</p><p><strong>Conclusion: </strong>Approximately one-third of studies reported the use of recruitment strategies; however, the overall implementation and standardization of these strategies remain low in asthma clinical trials. Standardization of recruitment and retention methodologies combined with well-defined recruitment objectives is necessary to improve diversity, equity, and inclusion in clinical trials.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing a hereditary angioedema prevalence for the United States using a large administrative claims database.","authors":"Anthony J Castaldo, Karen E Wells, Subhan Khalid, Emaan Rashidi, Christine N Selva, Deborah Corcoran, Sandra C Christiansen, Marc A Riedl, Bruce L Zuraw, Nilsa Loyo-Berrios","doi":"10.1016/j.anai.2025.05.018","DOIUrl":"https://doi.org/10.1016/j.anai.2025.05.018","url":null,"abstract":"<p><strong>Background: </strong>Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder. No US prevalence for all-types of HAE has been estimated. Approval of eight effective HAE therapies in the US significantly expanded treated patient numbers and data collected in claims databases.</p><p><strong>Objective: </strong>To provide the first US prevalence estimate of HAE (all-types) using claims-based insurance data.</p><p><strong>Methods: </strong>This retrospective study estimated the US prevalence of HAE using IQVIA's PharMetrics® Plus MedTech claims database. Patients with 24 months of continuous database enrollment were divided into 3 cohorts: 2018, 2019, 2020. Due to the absence of ICD-9-CM or ICD-10-CM diagnostic codes specific to HAE, we developed a proxy algorithm using ICD-10-CM codes for \"angioneurotic edema\" or \"defects in the complement system\" with ≥1 pharmacy claim for an HAE-indicated medication. An expert panel reviewed anonymized patient-level aggregate claims data to determine HAE status. A sensitivity analysis generated adjustment factors to address underrepresentation of Medicare patients in PharMetrics Plus MedTech database.</p><p><strong>Results: </strong>For 2018, 2019, and 2020, respectively, the claims-based algorithm yielded overall annual unadjusted HAE prevalence estimates per 100,000 and number of people diagnosed with HAE of 2.67, 9559; 2.61, 9341; and 2.43, 8694. The corresponding estimates based on expert physician analysis were 2.13, 7602; 2.03, 7275; and 1.84, 6595.</p><p><strong>Conclusion: </strong>Our study provides the first claims-based comprehensive estimate of the US prevalence for all-types of HAE across age-groups, sexes, and geographic regions. Our calculations (which exceed the commonly cited 2:100,000 prevalence for HAE with C1 inhibitor deficiency (C1INH)) afford a real-world projected prevalence encompassing all-types of HAE.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid Desensitization in Patients with Immediate Hypersensitivity to Antineoplastic Drugs: Clinical Outcomes and Risk Factors.","authors":"Lin Liang, Hyun Kyung Oh, Jae-Hyun Lee, Jung-Won Park, Kyung Hee Park","doi":"10.1016/j.anai.2025.05.010","DOIUrl":"https://doi.org/10.1016/j.anai.2025.05.010","url":null,"abstract":"<p><strong>Background: </strong>Hypersensitivity reactions to anticancer chemotherapy and monoclonal antibodies may necessitate discontinuation of the initial treatment. Rapid drug desensitization (RDD) is a proven, safe, and effective alternative strategy. However, a minority of patients still experience breakthrough reactions (BTRs) during RDD.</p><p><strong>Objective: </strong>To evaluate the clinical outcomes of RDD and identify risk factors for BTRs.</p><p><strong>Methods: </strong>We performed a retrospective analysis of cancer patients treated at Severance Hospital from May 2014 to October 2023. All patients experienced immediate hypersensitivity reactions to chemotherapy or monoclonal antibodies and underwent either a 2‑bag (for Grade 1 reactions) or a 4‑bag (for Grade 2-3 reactions), 11‑step RDD protocol.</p><p><strong>Results: </strong>A total of 1,010 RDD procedures were performed on 213 patients (157 platinum-based drugs, 31 taxanes, 16 monoclonal antibodies, 9 other drugs). Among them, 259 procedures used a 2-bag protocol, and 751 used a 4-bag protocol. BTRs occurred in 207 procedures (20.4%), involving 113 patients (53%). Most BTRs (n = 91) were associated with platinum-based agents, resulting in discontinuation in 15 cases. Logistic regression revealed that severe initial HSRs (OR = 2.101, 95% CI = 1.348-3.276, P = 0.001) and higher exposure frequency to chemotherapeutic agents (OR = 1.075, 95% CI = 1.010-1.144, P = 0.023) significantly increased the risk of moderate-to-severe BTRs. Overall, 95.8% of patients completed one or more therapy cycles.</p><p><strong>Conclusion: </strong>This 11-step RDD protocol is safe and effective in a diverse cancer population. It also demonstrated a direct association between more severe initial hypersensitivity reactions, previous high exposure to chemotherapeutic agents, and the occurrence of BTRs.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Future of therapy and monitoring for eosinophilic esophagitis and eosinophilic gastrointestinal diseases.","authors":"Andrew Dickerson, Evan S Dellon, Seema S Aceves","doi":"10.1016/j.anai.2025.05.016","DOIUrl":"https://doi.org/10.1016/j.anai.2025.05.016","url":null,"abstract":"<p><p>Eosinophilic gastrointestinal disorders, including eosinophilic esophagitis, are chronic Th2 mediated diseases. Establishing a diagnosis and initiating treatment is crucial to limit disease progression that may lead to tissue remodeling and the development of strictures that significantly impact patient quality of life. Expert consensus guidelines provide a framework for treating eosinophilic esophagitis with diet elimination, proton pump inhibitors, swallowed topical steroids, or dupilumab and for monitoring with sedated endoscopy for gross and histologic evaluation. While this provides an established algorithm for treating and monitoring eosinophilic esophagitis, there is less established for the rarer eosinophilic gastrointestinal disorders (eosinophilic gastritis, enteritis, and colitis). Research advancements continue to emerge at a rapid pace, identifying potential biomarkers, therapeutic targets, and monitoring strategies. In this article, we review the current accepted methods for treating and monitoring eosinophilic gastrointestinal disorders with a focus on eosinophilic esophagitis, assess what is currently under investigation, and provide an aspirational vision for future disease management with a streamlined algorithm of personalized medicine and less invasive monitoring.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to 'Highly accurate, noninvasive early identification of infants with a filaggrin loss-of-function mutation by in vivo Raman spectroscopy, followed from birth to 12 months' [Annals of Allergy, Asthma & Immunology, 134;4 (2025) 457-464].","authors":"Gerwin J Puppels, Jonathan O'B Hourihane, Claudio Nico, Carol Ni Chaoimh, Colin Wong, John E Common, Peter J Caspers, Alan D Irvine","doi":"10.1016/j.anai.2025.04.014","DOIUrl":"https://doi.org/10.1016/j.anai.2025.04.014","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144095724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intranasal Schirmer Test: A Useful Diagnostic Tool in Nasal Allergen Provocation Testing.","authors":"Paula von der Lage, David Bächinger, Silvan Marti, Peter Schmid-Grendelmeier, Christof Röösli, Claudia Lang, Michael Soyka","doi":"10.1016/j.anai.2025.05.012","DOIUrl":"https://doi.org/10.1016/j.anai.2025.05.012","url":null,"abstract":"<p><strong>Background: </strong>The intranasal Schirmer test (INSCH) is a quick method to objectify nasal secretion. This study aims to use the INSCH to assess nasal secretion change through direct nasal allergen provocation (NPT).</p><p><strong>Objective: </strong>This prospective single-center study included patients who received allergy diagnostics using NPT and anterior rhinomanometry (aRMM).</p><p><strong>Methods: </strong>The Schirmer filter paper was attached to the nasal septum bilaterally pre- and post-allergen provocation. Additionally, all participants completed the sinonasal outcome test 22 (SNOT-22). The difference in wetting length before and after allergen provocation was investigated. Moreover, a cut-off value for allergic rhinitis were calculated.</p><p><strong>Results: </strong>A total of n = 25 patients and n = 25 in the control group were included. Patients with a positive result in NPT showed a significantly higher secretion in the provoked nasal cavity (mean difference = 13.95 mm; p = 0.01). The increased moisture level through provocation resulted in an area under the curve (AUC) of 0.814. A cut-off value of 2.75 mm wetting length increase (Youden index = 0.532) was calculated (sensitivity = 81.8% and specificity = 71.4%). Allergy diagnostic patients scored significantly higher in the SNOT-22 than the control group (25.04 score difference; p < 0.001).</p><p><strong>Conclusion: </strong>The INSCH represents a straightforward and cost-effective test to assess intranasal secretion changes in allergy diagnostics. The incorporation of the INSCH in the NPT protocol could particularly enhance treatment efficacy for patients with inconclusive NPT results or it could serve as a substitute for other objective measurements like aRMM or acoustic rhinometry.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Respiratory Syncytial Virus on Asthma Development and Exacerbation.","authors":"Ruixue Ma, Chenyu Zhang, Yi Zhang, Hong Tan, Yao Zhang, Qiuhong Li, Yumei Bai, Xin Sun","doi":"10.1016/j.anai.2025.05.011","DOIUrl":"https://doi.org/10.1016/j.anai.2025.05.011","url":null,"abstract":"<p><p>Asthma is a chronic inflammatory disorder of the lower airways clinically characterized by recurrent wheezing, breathlessness, cough, and dyspnea, and is the most prevalent chronic disease among children and adolescents. Respiratory viral infections are implicated in asthma inception and exacerbation, with respiratory syncytial virus (RSV) emerging as a key contributor. RSV is a leading cause of acute lower respiratory tract infections (LRTIs), particularly infant bronchiolitis, and is associated with a type-2-biased immune response, diminished interferon activity, epithelial barrier dysfunction, and altered airway microbiome. While the causal relationship between RSV and asthma remains debated, early-life RSV LRTIs are increasingly recognized as a significant risk factor for recurrent wheezing and asthma-like symptoms in childhood. This review comprehensively evaluates existing evidence on the long-term respiratory outcomes of infant RSV infection, elucidates the pathophysiological mechanisms connecting RSV infection to asthma development-such as immune dysregulation, chronic airway inflammation, and gene-environment interplay-and highlights novel preventive strategies. Recent advancements, such as maternal RSV vaccines and long-acting monoclonal antibodies, demonstrate efficacy in reducing severe RSV disease burden and subsequent wheeze in high-risk infants. By bridging clinical observations with mechanistic insights, this review underpins the development of future clinical therapies.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Induced Allergic Rhinitis on Endogenous Epinephrine.","authors":"Thomas B Casale, Anne K Ellis, Carlos A Camargo, Jonathan M Spergel, David I Bernstein, John Oppenheimer, David M Fleischer, Sarina Tanimoto","doi":"10.1016/j.anai.2025.05.008","DOIUrl":"https://doi.org/10.1016/j.anai.2025.05.008","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}